BMJ Paediatrics Open

Clinicopathological discrepancies in the diagnoses of childhood causes of death in the CHAMPS network: An analysis of antemortem diagnostic inaccuracies

Haleluya Leulseged, ^{1,2,3} Christine Bethencourt, ⁴ Kitiezo Aggrey Igunza, ⁵ Victor Akelo, ^{6,7} Dickens Onyango, ⁸ Richard Omore, ⁵ Ikechukwu U Ogbuanu, ^{9,10} Soter Ameh, ^{9,11,12} Andrew Moseray, ⁹ Dickens Kowuor, ⁹ Ima-Abasi Bassey, ⁹ Shams El Arifeen, ¹³ Emily S Gurley, ^{13,14} Mohammad Zahid Hossain, ¹³ Afruna Rahman, ¹³ Muntasir Alam, ¹³ Nega Assefa, ^{1,3} Lola Madrid ⁽¹⁰⁾, ³ Addisu Alemu, ¹ Yasir Y Abdullahi, ¹ Karen L Kotloff, ¹⁵ Samba O Sow, ¹⁶ Milagritos D Tapia, ¹⁵ Nana Kourouma, ¹⁶ Seydou Sissoko, ¹⁶ Quique Bassat ⁽¹⁰⁾, ^{17,18,19,20,21} Rosauro Varo, ¹⁸ Inacio Mandomando ⁽¹⁰⁾, ^{17,18,21} Carla Carrilho, ^{22,23} Natalia Rakislova, ¹⁸ Fabiola Fernandes, ^{22,23} Shabir Madhi, ²⁴ Ziyaad Dangor, ²⁴ Sana Mahtab, ²⁴ Martin Hale, ²⁵ Vicky Baillie, ²⁴ Jeanie du Toit, ²⁴ Zachary J Madewell ⁽¹⁰⁾, ²⁶ Dianna M Blau, ²⁶ Roosecelis B Martines, ²⁷ Portia C Mutevedzi, ⁷ Robert F Breiman, ^{10,28} Cynthia G Whitney, ⁷ Chris A Rees ⁽¹⁰⁾, ²⁹ Child Health and Mortality Prevention Surveillance (CHAMPS) network

ABSTRACT

Introduction Determining aetiology of severe illness can be difficult, especially in settings with limited diagnostic resources, yet critical for providing life-saving care. Our objective was to describe the accuracy of antemortem clinical diagnoses in young children in high-mortality settings, compared with results of specific postmortem diagnoses obtained from Child Health and Mortality Prevention Surveillance (CHAMPS).

Methods We analysed data collected during 2016–2022 from seven sites in Africa and South Asia. We compared antemortem clinical diagnoses from clinical records to a reference standard of postmortem diagnoses determined by expert panels at each site who reviewed the results of histopathological and microbiological testing of tissue, blood, and cerebrospinal fluid. We calculated test characteristics and 95% CIs of antemortem clinical diagnostic accuracy for the 10 most common causes of death. We classified diagnostic discrepancies as major and minor, per Goldman criteria later modified by Battle. Results CHAMPS enrolled 1454 deceased young children aged 1-59 months during the study period; 881 had available clinical records and were analysed. The median age at death was 11 months (IQR 4-21 months) and 47.3% (n=417) were female. We identified a clinicopathological discrepancy in 39.5% (n=348) of deaths; 82.3% of diagnostic errors were major. The sensitivity of clinician antemortem diagnosis ranged from 26% (95% CI 14.6% to 40.3%) for non-infectious respiratory diseases (eq. aspiration pneumonia, interstitial

lung disease, etc) to 82.2% (95% Cl 72.7% to 89.5%) for diarrhoeal diseases. Antemortem clinical diagnostic specificity ranged from 75.2% (95% Cl 72.1% to 78.2%) for diarrhoeal diseases to 99.0% (95% Cl 98.1% to 99.6%) for HIV.

Conclusions Antemortem clinical diagnostic errors were common for young children who died in areas with high childhood mortality rates. To further reduce childhood mortality in resource-limited settings, there is an urgent need to improve antemortem diagnostic capability through advances in the availability of diagnostic testing and clinical skills.

INTRODUCTION

Despite more than a 50% reduction in childhood mortality rates since the 1990s, an estimated 5.2 million deaths occurred among children aged <5 years in 2019.¹ Over 80% of deaths among children aged <5 years occur in sub-Saharan Africa and South Asia.² Disparate rates in childhood mortality are attributable, in part, to high rates of childhood malnutrition, infections, poverty, and poor access to the health system, which are common in sub-Saharan Africa and South Asia.³

In addition to these factors that contribute to high rates of childhood mortality in these regions, prior studies suggest that as much

To cite: Leulseged H, Bethencourt C, Igunza KA, *et al.* Clinicopathological discrepancies in the diagnoses of childhood causes of death in the CHAMPS network: An analysis of antemortem diagnostic inaccuracies. *BMJ Paediatrics Open* 2024;**8**:e002654. doi:10.1136/ bmjpo-2024-002654

► Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/ 10.1136/bmjpo-2024-002654).

HL and CB contributed equally. CGW and CAR contributed equally.

HL and CB are joint first authors. CGW and CAR are joint senior authors.

(I) Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Chris A Rees; chrisrees2@ gmail.com



WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ A significant proportion (58%–77%) of deaths among young children in sub-Saharan Africa and South Asia are preventable with timely access to high-quality clinical care, which includes accurate diagnoses.

WHAT THIS STUDY ADDS

- ⇒ Using data from 881 deaths among infants and children aged 1–59 months from the 10 most common causes determined through extensive postmortem examinations in 7 countries, we documented antemortem diagnostic errors in 39.5% of cases, with 82.3% of those diagnostic errors being considered major.
- ⇒ To further reduce childhood mortality in resource-limited settings, there is an urgent need to improve antemortem diagnostic capability.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ Enhancing antemortem diagnostic capacity is a crucial step towards directing appropriate clinical care to children in regions with high childhood mortality rates in sub-Saharan Africa and South Asia.
- ⇒ The comparison of common antemortem clinical diagnostic errors compared with postmortem determined causes of death identifies the disease processes in most need of improved diagnostic approaches.

as 58%–77% of childhood deaths in resource-limited settings could have potentially been averted with more timely access to high-quality clinical care.⁴⁵ Limited access to laboratory and radiographic diagnostic tests, resulting in inaccurate diagnoses and subsequent inappropriate patient treatment contribute to high rates of childhood mortality in sub-Saharan Africa and South Asia.^{6–8} In a previous study, when antemortem and postmortem diagnoses aligned, clinician adherence to clinical care recommendations was higher.⁹ Thus, making correct diagnoses is key to improving clinical care in resource-limited settings with high rates of childhood mortality.

A comparison of antemortem clinical diagnoses to postmortem-determined causes of death may help identify the most relevant diagnostic improvements to potentially reduce deaths among children aged <5 years. Previous studies suggest that rates of discrepancies in antemortem clinical diagnoses and postmortem diagnoses range from 20% of childhood deaths in the USA and Chile to 38% of maternal deaths in Mozambique and 40% of deceased adults in South America, using complete diagnostic autopsy as the reference standard.^{10–13} However, studies on the accuracy of antemortem diagnoses among young children are lacking in regions with high rates of childhood mortality in sub-Saharan Africa and South Asia.

Our objective was to evaluate antemortem clinical diagnostic accuracy compared with causes of death determined by postmortem investigation among infants and children aged 1–59 months who died in seven sites in sub-Saharan Africa and South Asia participating in Child Health and Mortality Prevention Surveillance (CHAMPS). Moreover, we aimed to describe factors

associated with major (ie, an accurate diagnosis could have impacted survival) antemortem diagnostic errors compared with postmortem causes of death. Such an understanding is a necessary step towards health systems' strengthening and allocating the most crucial diagnostic resources to correctly diagnose children, improve clinical outcomes, and potentially reduce childhood mortality.

METHODS Study dooi

Study design

We conducted a descriptive study and analysed data from seven sites in sub-Saharan Africa and Bangladesh participating in the CHAMPS Network. CHAMPS is conducting prospective mortality surveillance in healthcare centres and communities in areas of high mortality among children aged <5 years (ie, >50 per 1000 live births).^{14 15}

Patient and public involvement

The development of the research question was informed by the large burden child mortality worldwide. Patients were not involved in the design, recruitment or conduct of the study. Results of this study will be made publicly available through publication where study participants may access them. Patients were not advisers in this study.

Study setting

The CHAMPS Network was established in 2015 and includes sites in Baliakandi and Faridpur, Bangladesh; Kersa, Haramaya and Harar, Ethiopia; Kisumu and Siaya, Kenya; Bamako, Mali; Manhiça and Quelimane, Mozambique; Makeni and Bo, Sierra Leone; and Soweto, South Africa.¹⁶ These regions were selected because they have high rates of mortality among children aged <5 years. CHAMPS employs postmortem pathological and microbiological evaluations to ascertain causes of child deaths, with the aim of preventing deaths by informing policies and programmes.¹⁷

Population and inclusion and exclusion criteria

Our study population included all infants and children aged 1-59 months who died and were enrolled in CHAMPS from December 2016 to February 2022 and had documented antemortem clinical diagnoses. CHAMPS enrols stillbirths and deaths among neonates, infants and children that occur in health facilities or in the community. Here, we focused our analyses on deceased infants and children (1) with identifiable antemortem clinical diagnoses within their clinical records, (2) with consenting caregivers, (3) who underwent minimally invasive tissue sampling (MITS), and had adequate samples to determine causes of death and (4) whose results were reviewed by expert panels to determine postmortem pathology-based diagnoses. We excluded cases without clinical records and those who died before presentation to a health facility because antemortem clinical diagnoses could not be determined for these deaths.

Study procedures

Surveillance for stillbirths and child deaths occurring in healthcare facilities and the community is performed by CHAMPS staff at each site. CHAMPS enrols cases within 24 hours of death for the MITS procedure. Within this time frame, caregivers of deceased neonates, infants and children are informed about the CHAMPS data collection process and approached for potential enrolment in the study.¹⁵¹⁸ CHAMPS procedures include the collection of demographic information, clinical record review, verbal autopsy, and extensive postmortem tissue sampling and testing. Briefly, MITS consists of collection of tissue samples from brain, lungs, liver, and heart using biopsy needles, in addition to samples of blood and cerebrospinal fluid using syringes. Moreover, nasopharyngeal and rectal swabs are collected. MITS serves as a proxy for complete diagnostic autopsy and has demonstrated high concordance, for all age groups, with complete diagnostic autopsy.¹⁹⁻²¹ All collected samples undergo histopathological and microbiological analyses including H&E staining, targeted histochemistry, and immunohistochemistry dictated by the morphological findings and molecular pathogen identification through extensive PCR testing for 126 different pathogens (TaqMan array; ThermoFisher Scientific, Waltham, Massachusetts, USA).^{17 22}

Tissues and body fluids are sent for culture. Blood samples also undergo HIV PCR testing, malaria thick and thin smears, and TaqMan array PCR testing (including the screening of 126 pathogens) and microbial culture.²² Nasopharyngeal, oropharyngeal, and rectal swabs are sent for TaqMan array PCR testing. Samples are reviewed by anatomical pathologists who have received specific training for the CHAMPS study at each site, as well as by a central pathology lab at the US Centers for Disease Control and Prevention.²³

To comprehensively capture clinicians' diagnostic considerations and to determine antemortem clinical diagnoses, CHAMPS staff extracted all diagnoses recorded during the last clinical encounter before the infant's or child's death. These data were abstracted from all available admission forms, progress notes, laboratory results, and radiographic test results.

All clinical, verbal autopsy, histopathological, and microbiological results were subsequently reviewed through a standardised process by CHAMPS Determination of Cause of Death (DeCoDe) panels, which are composed of experts across various fields, including paediatricians, pathologists, microbiologists, medical epidemiologists, local public health officials, and representatives of local ministries of health.¹⁷ They use antemortem clinical data, which includes clinicians' documentation of clinical history, progress notes, laboratory and radiographic imaging results, postmortem MITS pathological results, microbiological results, and verbal autopsy data to determine the underlying cause of death, as well as the comorbid and immediate conditions contributing to death in all enrolled cases. The

clinical diagnoses considered as antemortem diagnoses included all diagnoses documented from the time of the child's clinical encounter to the time of the child's death, which included diagnoses at admission (including known chronic diseases such as HIV), interim diagnoses and final diagnoses. To comprehensively capture all documented causes for each case of death, we analysed all levels of diagnoses along the causal chain of mortality. The causal chain of mortality refers to all causes of death documented for each case, including the underlying cause of death, immediate cause of death that directly preceded terminal events, and comorbid conditions contributing to death. Determined causes of death are coded in agreement with the International Classification of Diseases, 10th Revision and the WHO death certificate.¹⁷

Variables

Each documented antemortem clinical diagnosis was compared with causes of death as determined by DeCoDe panels, which served as the reference standard. Overall, the 10 most common causes of death as determined by DeCoDe panels based on the aggregated CHAMPS data were (1) lower respiratory infections, (2) sepsis, (3) malnutrition, (4) malaria, (5) diarrhoeal diseases, (6) HIV, (7) congenital birth defects, (8) anaemia, (9) other respiratory disease (ie, non-infectious syndromes including aspiration pneumonia, interstitial lung disease and pulmonary haemorrhage), and (10) meningitis/ encephalitis.²⁴

Each documented antemortem clinical diagnosis was paired with each postmortem cause of death for every case. For cases with multiple postmortem causes of death, all postmortem causes of death were included (ie, immediate, underlying or comorbid). We classified each potential antemortem and postmortem diagnostic pairing that were discrepant as major (class I or class II) or minor (class III or class IV) diagnostic errors, following the criteria originally developed by Goldman and later modified by Battle.^{25 26} Two authors with clinical training in paediatrics (CB and CAR) independently reviewed each diagnostic pairing to classify them according to the established system. Any disagreements between these two reviewers were discussed until consensus was reached for each diagnostic pairing. Class I errors included errors in which 'knowledge of the correct diagnosis before death would have impacted clinical management decisions that could have resulted in either cure or prolonged survival' (eg, sepsis treated as malnutrition).^{25 26} Class II diagnostic errors were those in which the impact on survival was equivocal despite the misdiagnosis for primary diagnoses, such as cases in which there was ambiguity on whether the correct diagnosis would have changed outcomes²⁶ (eg, lower respiratory tract infections treated as sepsis). Class III included missed diagnoses with symptoms that should have been treated because they were either related to the terminal disease but not directly responsible for death or could have eventually impacted prognosis²⁵ (eg, congenital birth defects treated as anaemia). Class IV diagnostic discrepancies included undiagnosed diseases that carried either genetic or epidemiological importance and may have eventually impacted prognosis²⁶ (eg, sickle cell disease treated as anaemia alone). Correctly diagnosed patients were categorised as class V. Deaths that were non-classifiable due to unclear antemortem clinical diagnoses or insufficient postmortem information were categorised as class VI.

Statistical analyses

Sensitivity, specificity and area under the curve (AUC) of each antemortem clinical diagnosis were calculated compared with each postmortem cause of death. We calculated the positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, proportion correctly diagnosed, and apparent and true prevalence for antemortem diagnoses for each cause of death. We used Cohen's Kappa to determine agreement between antemortem diagnoses and postmortem-determined causes of death.²⁷ For deaths with multiple antemortem clinical diagnoses or multiple postmortem causes of death, each antemortem diagnosis was compared with each postmortem cause of death and considered a match if the antemortem clinical diagnosis was in any location in the causal chain determined by the expert panel at each site.

To identify the diseases in which antemortem clinical diagnoses had the most optimal sensitivity and specificity, we calculated the Youden's index,²⁸ which allows for the quantification of the overall diagnostic performance. We calculated the number needed to diagnose, which is the number of patients that need to be diagnosed antemortem to identify one correctly diagnosed patient. We calculated 95% CIs for all measures. We used mixedeffect univariable and multivariable logistic regression to identify factors associated with major diagnostic errors, including age, sex, time from hospital admission to death, the number of postmortem diagnoses, and site as candidate variables. The selection of these candidate variables for the inclusion in the model was predicated on their potential influence on diagnostic errors. Age, for instance, might influence disease presentation in children while the time from admission to death could impact disease progression and recognition of signs and symptoms. The number of postmortem diagnoses and site were included due to potential variations in healthcare infrastructure, diagnostic capabilities and disease prevalence across different regions. As diagnostic capacity and patient complexity may vary across CHAMPS sites, we introduced an interaction term between site and number of causes of death. We also conducted sensitivity analyses to determine the test characteristics of antemortem clinician diagnosis to postmortem determined causes of death by site, sex, age (ie, 1-11 months and 12-59 months) and duration of hospital admission (ie, <24 hours and \geq 24 hours). All statistical analyses were performed by using R software, V.4.3.1 (R Foundation for Statistical Computing).

RESULTS

CHAMPS enrolled 1454 deaths in infants and children aged 1-59 months from December 2016 to February 2022. Of these, 498 did not have antemortem clinical records available and 75 died prior to presentation at a health facility, leaving 881 (60.5%) deaths that were included in the analyses (online supplemental figure 1). Included cases did not differ from excluded cases by age or sex but differed by site of enrolment (online supplemental table 1). The median age at the time of death was 11 months (IQR 4–21 months) and 47.3% (n=417) were female. The majority (74.6%, n=657) died in hospital and the other 224 (25.4%) died at home following clinical encounters. Cases were distributed across the seven sites as follows: Kenya (25.9%, n=228), Sierra Leone (24.4%, n=215), South Africa (18.6%, n=164), Mali (15.3%, n=135), Mozambique (10.0%, n=88), Bangladesh (3.3%, n=29) and Ethiopia (2.5%, n=22) (table 1).

Antemortem clinical diagnoses

The most common antemortem diagnoses among the included cases were malaria (31.8%, n=280), diarrhoeal disease (30.7%, n=270), lower respiratory tract infections (30.5%, n=269) and malnutrition (22.6%, n=199) (table 1).

Postmortem determined causes of death

Overall, the most common causes of death anywhere in the causal chain of death were lower respiratory tract infections (31.1%, n=274), sepsis (29.3%, n=258), and malnutrition (19.0%, n=167; table 1). The most common underlying causes of death determined through postmortem examinations were malnutrition (13.5%, n=119), malaria (8.7%, n=77), and HIV (7.7%, n=68) (online supplemental table 2). The most common immediate causes of death were sepsis (21.5%, n=189), lower respiratory tract infections (14.2%, n=125), and malaria (5.6%, n=49). Lower respiratory tract infections (12.5%, n=110), sepsis (6.6%, n=58), and anaemias (7.2%, n=63) were the most common comorbid causes of death. When there was only one cause of death determined postmortem, the most common conditions were malaria (n=43), lower respiratory infections (n=22), and diarrhoeal diseases (n=17).

Test characteristics of antemortem clinical diagnoses

A total of 635 diagnostic pairs between antemortem clinician diagnosis and postmortem causes of death were concordant. There were 64 diagnostic pairs between antemortem clinician diagnosis and postmortem causes of death that were unclassifiable. Malaria and diarrhoeal diseases were most often correctly diagnosed in the antemortem period (online supplemental table 3). Anaemias, meningitis/encephalitis, and respiratory diseases other than lower respiratory tract infections (ie, aspiration pneumonia, interstitial lung disease and pulmonary haemorrhage) were most infrequently diagnosed among the top 10 causes of death. Table 1Description of deceased infants and childrenincluded in the analyses and causes of death identifiedby Child Health and Mortality Prevention Surveillancedetermination of cause of death process (N=881) who diedfrom 2016 to 2022

	n (%)
Age in months (median, IQR)*	11 (4–21)
Female	417 (47.3)
Site	
Bangladesh	29 (3.3)
Ethiopia	22 (2.5)
Kenya	228 (25.9)
Mali	135 (15.3)
Mozambique	88 (10.0)
Sierra Leone	215 (24.4)
South Africa	164 (18.6)
Most common antemortem clinician dia	ignoses
Malaria	280 (31.8)
Diarrhoeal disease	270 (30.7)
Lower respiratory tract infections	269 (30.5)
Malnutrition	199 (22.6)
Anaemia	170 (19.3)
Sepsis	157 (17.8)
Severe dehydration	91 (8.5)
Congenital birth defects	81 (9.2)
Meningitis	68 (7.7)
Seizure	58 (6.6)
Most common postmortem determined	causes of death

Most common postmortem determined causes of death anywhere in the causal chain of death

Lower respiratory tract infections	274 (31.1)
Sepsis	258 (29.3)
Malnutrition	167 (19.0)
Malaria	142 (16.1)
Diarrhoeal diseases	90 (10.2)
HIV	68 (7.7)
Congenital birth defects	63 (7.2)
Anemias	93 (10.6)
Other respiratory disease†	50 (5.7)
Meningitis/encephalitis	49 (5.6)

*Two cases had missing age but were categorised as infants or children at the time of death.

†Non-infectious respiratory conditions such aspiration pneumonia, interstitial lung disease and pulmonary haemorrhage.

The sensitivity of antemortem clinical diagnosis ranged from 26.0% (95% CI 14.6% to 40.3%) for the category of other respiratory diseases to 82.2% (95% CI 72.7% to 89.5%) for diarrhoeal diseases (table 2). The specificity of antemortem clinical diagnosis ranged from 75.2% (95% CI 72.1% to 78.2%) for diarrhoeal diseases to 99.0% (95% CI 98.1% to 99.6%) for HIV (table 2). The AUC for antemortem clinical diagnoses compared with postmortem determined cause of death ranged from 0.56 for anaemias to 0.91 for HIV (figure 1).

The positive likelihood ratio of clinician antemortem diagnoses ranged from 2.12 (95% CI 1.56 to 2.88) for anaemias to 67.25 (95% CI 33.06 to 136.81) for HIV (online supplemental table 4). Negative likelihood ratios of clinician antemortem diagnoses ranged from 0.25 (95% CI 0.18 to 0.36) for malaria to 0.77 (95% CI 0.65 to 0.91) for other respiratory diseases. The overall diagnostic accuracy of clinician antemortem diagnoses was highest for HIV (Youden's index 0.65, 95% CI 0.52 to 0.77) and lowest for anaemias (Youden's index 0.19, 95% CI 0.07 to 0.33). There were 464 cases in our analyses that had >1 postmortem-determined cause of death. Of these, the majority (83.6%, n=388) did not have all postmortem causes of death diagnosed prior to the child's death.

Major and minor diagnostic discrepancies

A discrepancy between antemortem clinical diagnosis and postmortem determined causes of death was identified in 39.5% (n=348/881) cases. A total of 555 diagnostic errors were identified among 1254 diagnostic comparisons between antemortem clinical diagnoses and postmortem causes of death (table 3). Among the 555 diagnostic errors, 457 (82.3%) were classified as major and 98 (17.7%) as minor. Major antemortem diagnostic errors were most common among infants and children who died from meningitis/encephalitis (63.3%, n=31) and sepsis (54.2%, n=140), and least common among diagnostic pairs in cases of congenital birth defects (3.2%, n=2) and malaria (13.4%, n=19) (table 3). Minor diagnostic errors were most common among cases that died from anaemias (43.0%, n=40) and congenital birth defects (31.7%, n=20).

In multivariable analyses, infants and children who had 2–3 postmortem causes of death (adjusted OR (aOR) 33.9, 95% CI 17.4 to 73.2) and >3 postmortem causes of death (aOR 90.5, 95% CI 42.7 to 210.3) were more likely to have a major antemortem diagnostic error than those who had only one postmortem cause of death (table 4). The interaction term between site and the number of causes of death did not reach statistical significance (p=0.428), which suggests that number of causes of death exerted an effect independent of site. Age, sex, duration of hospital admission and site were not associated with the presence of a major diagnostic error.

Sensitivity analyses

The sensitivity and specificity of clinician antemortem diagnoses compared with postmortem causes of death varied by site (online supplemental table 5). However, test characteristics of antemortem diagnoses did not vary substantially by the sex (online supplemental table 6) or age of the deceased infant or child (online supplemental table 7). The sensitivity of antemortem clinician diagnoses was generally higher among infants and children


	١
6	J
U	5

Table 2Comparison of clinician antemortem diagnosis and CHAMPS sites from 2016 to 2022	barison of clii from 2016 to	nician antemo 2022	ortem diagnos	is and postmo	postmortem causes of death for N=881 deaths among infants and children aged 1–59 months enrolled in	h for N=881 deaths a	among infants and ch	iildren aged 1–59 m	onths enrolled in
Cause of death Test characteristics of clinician antemortem	Test charac	teristics of cl	inician antem	ortem diagno.	diagnosis compared with postmortem determined cause of death	ostmortem determine	ed cause of death		
determined True True postmortem by positives, n negatives, CHAMPS (%) n (%)	True positives, n (%)	True n negatives, n (%)	False False positives, n negatives, (%) n (%)	False negatives, n (%)	Sensitivity % (95% Cl)	Sensitivity % (95% Specificity % (95% Positive predictive Cl) Cl) value % (95% Cl)	Positive predictive value % (95% Cl)	Negative predictive value % Cohen's Kappa (95% Cl) (95% Cl)	Cohen's Kappa (95% Cl)
Lower respiratory tract infection	130 (14.8)	466 (52.9)	141 (16.0)	144 (16.3)	47.4 (41.4 to 53.5)	76.8 (73.2 to 80.1)	48.0 (41.9 to 54.1)	76.4 (72.8 to 79.7)	0.24 (0.17 to 0.31)
Sepsis	96 (10.9)	560 (63.6)	63 (7.2)	162 (18.4)	37.2 (31.3 to 43.4)	89.9 (87.2 to 92.1)	60.4 (52.3 to 68.0)	77.6 (74.3 to 80.6)	0.30 (0.23 to 0.37)
Malnutrition	77 (8.7)	592 (67.2)	122 (13.8)	90 (10.2)	46.1 (38.4 to 54.0)	82.9 (79.9 to 85.6)	38.7 (31.9 to 45.8)	86.8 (84.0 to 89.3)	0.27 (0.20 to 0.34)
Malaria	114 (12.9)	572 (64.9)	167 (19.0)	28 (3.2)	80.3 (72.8 to 86.5)	77.4 (74.2 to 80.4)	40.6 (34.8 to 46.6)	95.3 (93.3 to 96.9)	0.42 (0.35 to 0.48)
Diarrhoeal diseases	74 (8.4)	595 (67.5)	196 (22.2)	16 (1.8)	82.2 (72.7 to 89.5)	75.2 (72.1 to 78.2)	27.4 (22.2 to 33.1)	97.4 (95.8 to 98.5)	0.30 (0.24 to 0.37)
HIV	45 (5.1)	805 (91.4)	8 (0.9)	23 (2.6)	66.2 (53.7 to 77.2)	99.0 (98.1 to 99.6)	84.9 (72.4 to 93.3)	97.2 (95.9 to 98.2)	0.73 (0.63 to 0.82)
Congenital birth 35 (4.0) defects	35 (4.0)	772 (87.6)	46 (5.2)	28 (3.2)	55.6 (42.5 to 68.1)	94.4 (92.6 to 95.9)	43.2 (32.2 to 54.7)	96.5 (95.0 to 97.7)	0.44 (0.34 to 0.55)
Anaemias	34 (3.9)	652 (74.0)	136 (15.4)	59 (6.7)	36.6 (26.8 to 47.2)	82.7 (79.9 to 85.3)	20.0 (14.3 to 26.8)	91.7 (89.4 to 93.6)	0.14 (0.07 to 0.22)
Other respiratory diseases*	13 (1.5)	797 (90.5)	34 (3.9)	37 (4.2)	26.0 (14.6 to 40.3)	95.9 (94.3 to 97.2)	27.7 (15.6 to 42.6)	95.6 (93.9 to 96.9)	0.23 (0.11 to 0.35)
Meningitis/ encephalitis	14 (1.6)	778 (88.3)	54 (6.1)	35 (4.0)	28.6 (16.6 to 43.3)	93.5 (91.6 to 95.1)	20.6 (11.7 to 32.1)	95.7 (94.1 to 97.0)	0.19 (0.08 to 0.29)
*Includes aspiration pneumonia, interstitial lung disease, and pulmonary haemorrhage. CHAMPS, Child Health and Mortality Prevention Surveillance.	ion pneumoni Health and M	ia, interstitial lu ortality Prevent	ing disease, an tion Surveillanc	d pulmonary h: :e.	aemorrhage.				

6

Figure 1

worthless discrimination.



antemortem clinical diagnoses compared with postmortem

months who died in one of seven sites in the Child Health

and Mortality Prevention Surveillance network (data collected

representing perfect discriminatory ability and 0.5 suggesting

who were admitted for ≥ 24 hours than those admitted

for <24 hours prior to death. For instance, the sensitivity

for lower respiratory tract infection in infants aged 1-11

months was 49.7% (95% CI 41.6% to 57.8%), for sepsis

it was 47.7% (95% CI 39.4% to 56.0%) and for malnu-

trition it was 46.9% (95% CI 35.7% to 58.3%) (online

causes of death among infants and children aged 1-59

during 2016-2022). The area under the curve provides an aggregate measure of diagnostic precision, with 1.0

Open access

supplemental table 8). Similar patterns were observed among those who had only one cause of death determined postmortem compared with those with more than one cause of death (online supplemental table 9). The sensitivity and specificity of clinical antemortem diagnoses made at the final clinical encounter were generally lower for cases that died at home than among cases that died during hospital admission (online supplemental table 10).

DISCUSSION

In our study of 881 deceased infants and children, we found that diagnostic errors were common when antemortem clinical diagnoses were compared with postmortem causes of death, which highlights the need for enhanced diagnostic approaches for young children. Many of the diagnostic discrepancies observed were major. Moreover, there were greater odds of antemortem clinical diagnostic errors among children who died from >1 cause. These findings underscore the limitations of clinical diagnosis and the critical need for improved diagnostic tools and techniques to reduce childhood mortality in resource-limited settings. Notably, many children died despite alignment between antemortem and postmortem diagnoses, underscoring that accurate diagnosis alone is insufficient to reduce childhood mortality but is a key step towards the provision of high-quality clinical care.

Approximately 40% of all deaths among infants and children in our study had at least one diagnostic error.

	Major errors		Minor errors		No error	Could not determine	
Postmortem CHAMPS determined cause of death	Class I,* n (%)	Class II,† n (%)	Class III,‡ n (%)	Class IV,§ n (%)	Class V,¶ n (%)	Class VI,** n (%)	Total, n
Lower respiratory tract infection	86 (31.4)	33 (12.0)	11 (4.0)	2 (0.7)	128 (46.7)	14 (5.1)	274
Sepsis	127 (49.2)	13 (5.0)	6 (2.3)	4 (1.6)	96 (37.2)	12 (4.7)	258
Malnutrition	76 (45.5)	0 (0)	0 (0)	0 (0)	78 (46.7)	13 (7.8)	167
Malaria	19 (13.4)	0 (0)	0 (0)	1 (0.7)	113 (79.6)	9 (6.3)	142
Anaemias	15 (16.1)	0 (0)	0 (0)	40 (43.0)	35 (37.6)	3 (3.2)	93
Diarrhoeal diseases	15 (16.7)	0 (0)	0 (0)	0 (0)	74 (82.2)	1 (1.1)	90
HIV	17 (25.0)	0 (0)	0 (0)	1 (1.5)	45 (66.2)	5 (7.4)	68
Congenital birth defects	2 (3.2)	0 (0)	0 (0)	20 (31.7)	39 (61.9)	2 (3.2)	63
Other respiratory diseases ^{††}	22 (44.0)	1 (2.0)	9 (18.0)	2 (4.0)	13 (26.0)	3 (6.0)	50
Meningitis/encephalitis	22 (44.9)	9 (18.4)	1 (2.0)	1 (2.0)	14 (28.6)	2 (4.1)	49

Table 3 Distribution of antemortem clinical diagnostic errors by class for the top 10 causes of death among infants and children aged 1-59 months enrolled in CHAMPS sites from 2016 to 2022

*Errors that may have impacted survival if properly diagnosed/treated.

†Errors in which impact on survival was equivocal despite the misdiagnosis for primary diagnoses.

‡Missed diagnoses not directly responsible for death.

§Missed diagnoses with genetic/epidemiological importance.

¶Antemortem and postmortem diagnoses aligned.

**Deaths that were non-classifiable due to unclear antemortem clinical diagnoses or insufficient postmortem information.

††Includes aspiration pneumonia, interstitial lung disease and pulmonary haemorrhage.

CHAMPS, Child Health and Mortality Prevention Surveillance.

	Minor or no diagnostic error, n (%)	Major diagnostic error, n (%)		Durality		Dualas
	N=381	N=255	OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Age at the time of d				0.807		0.985
1–11 months	198 (52.0)	130 (51.0)	Referent			
12–59 months	183 (48.0)	125 (49.0)	1.04 (0.76 to 1.43)		1.00 (0.65 to 1.53)	
Sex				0.785		0.365
Male	199 (52.2)	136 (53.3)	1.05 (0.76 to 1.44)		1.21 (0.80 to 1.83)	
Female	182 (47.8)	119 (46.7)	Referent			
Time from admissio	n to death			0.163		0.378
<24 hours	163 (42.8)	95 (37.3)	Referent			
≥24 hours	218 (57.2)	160 (62.7)	1.26 (0.91 to 1.75)		0.81 (0.51 to 1.28)	
Number of postmor	tem diagnoses			< 0.001		< 0.001
1	240 (63.0)	10 (3.9)	Referent		Referent	
2–3	108 (28.3)	136 (53.3)	30.22 (16.03 to 63.45)		33.90 (17.42 to 73.18)	
>3	33 (8.7)	109 (42.7)	79.27 (39.38 to 175.96)		90.48 (42.73 to 210.25)	
Site				< 0.001		0.477
Bangladesh†	5 (1.3)	1 (0.4)				
Ethiopia†	4 (1.0)	5 (2.0)				
Kenya	80 (21.0)	51 (20.0)	0.54 (0.34 to 0.87)		1.41 (0.78 to 2.58)	
Mali	60 (15.7)	10 (3.9)	0.14 (0.06 to 0.29)		1.03 (0.37 to 2.83)	
Mozambique	45 (11.8)	31 (12.2)	0.59 (0.33 to 1.02)		1.42 (0.70 to 2.89)	
Sierra Leone	118 (31.0)	76 (29.8)	0.55 (0.36 to 0.84)		1.67 (0.93 to 3.02)	
South Africa	69 (18.1)	81 (31.8)	Referent		Referent	

*Excludes children who were dead on arrival or missing hospital duration, as well as unclassifiable diagnostic pairs (class VI). †Bangladesh and Ethiopia were excluded from regression analysis due to low cell counts.

This rate is higher than prior studies among deceased children that have demonstrated clinicopathological discrepancy rates ranging from 19% among children in Chile¹¹ to 30% among children in China.²⁹ The higher rate of clinicopathological discrepancies observed in our study compared with prior studies among children is likely due to several reasons. First, laboratory capabilities in low- and middle-income countries are often more limited than that found in settings with more resources,^{7 30} which may hinder the determination of timely and accurate antemortem diagnoses. Prior studies also suggest commonly used clinical signs and symptoms for diagnosing lower respiratory tract infections can be non-specific and difficult to detect correctly in young children, making accurate diagnosis of these conditions challenging.³¹ Accurate diagnoses among young children may also be more challenging given non-specific symptoms for many conditions, which has prompted the development of risk assessment tools that make use of combined signs and symptoms to augment diagnostic and prognostic accuracy,^{32 33} though these tools are not yet widely used.

Major diagnostic errors were more common among infants and children who had more than one cause of death. Children with more comorbid illnesses may have greater disease complexity that poses diagnostic challenges. Clinicians may prioritise diagnosing and treating one predominant condition while other comorbid illnesses are missed or not highlighted for treatment decisions. Additionally, overlapping signs and symptoms between concurrent diseases can complicate making accurate diagnoses. This finding may also represent underdocumentation of antemortem clinical diagnoses. However, we had no reason to believe that underdocumentation would be more common among children who died from >1 cause.

Clinician antemortem diagnosis of malaria had the highest sensitivity in our study. Owing to the historically large burden of malaria-related mortality, much attention has been paid to developing simple and accurate diagnostic tools including malaria rapid diagnostic tests and malaria parasite smears.³⁴ However, the accuracy of malaria rapid diagnostic tests is limited by the persistence of positive results for weeks after successful

treatment and cure. This may lead to clinician overdiagnosis of malaria by clinicians based on positive rapid diagnostic tests, even with resolved infection, contributing to the low positive predictive value of 40.6% we observed. Moreover, in malaria-endemic areas, individuals can be infected but not necessarily have any clinical consequence of those infections, given the partial natural immunity progressively acquired to this disease. The availability of such rapid diagnostics, as well as a high pretest probability in malaria-endemic settings, may have contributed to high sensitivity of antemortem clinician diagnosis. As the sensitivity of clinician antemortem diagnoses was low for the other included diseases, our results suggest that additional rapid, simple, accurate and clinically relevant diagnostics and point-of-care testing in settings with limited laboratory capacity may be needed to enhance diagnostic accuracy for conditions such as lower respiratory tract infections and sepsis.

The sensitivity of antemortem clinical diagnosis for common causes of death such as lower respiratory tract infections and sepsis was below 50%, rendering many of these diagnoses unrecognised while the child was alive. Moreover, the sensitivity of antemortem clinical diagnosis for other respiratory diseases (ie, aspiration pneumonia, interstitial lung disease, and pulmonary haemorrhage) was the lowest among the conditions considered. Potential factors contributing to this suboptimal diagnostic accuracy could include the lack of access to radiologic imaging, which may hinder the accurate identification of lung-related abnormalities.³⁵ Additionally, the presence of non-specific signs and symptoms commonly associated with respiratory illnesses might further complicate precise diagnosis.

Limitations

The results of our study should be interpreted in the context of several limitations. First, clinical data collected in the CHAMPS network relies on documentation by treating clinicians and nurses, which at times may be incomplete and may not have included all antemortem clinical diagnoses. Some diagnoses considered by treating clinicians may not have been documented, leading to a potential overestimation or underestimation, of clinicopathological discrepancies. Respiratory diseases, such as pneumonia, are often the terminal event preceding death. Therefore, symptoms on admission may not always translate to the cause of death determined postmortem. There is also the potential difficulty in differentiating between transient or asymptomatic bacteraemia/positive culture and sepsis or SIRS, as the determination of sepsis was based on culture sampling via MITS and required careful consideration of clinical context and symptoms, which may not always be clearly documented or distinguishable in antemortem records.

This discordance in symptoms at presentation through disease progression could contribute to the low sensitivity observed for other respiratory diseases in our analyses. We attempted to overcome these potential limitations by thorough review of all available clinical data by trained clinicians with familiarity with local contexts. We did not assess the relationship between the timing that the diagnosis was made and the postmortem-determined causes of death. As illnesses progress and patients can develop secondary illnesses, future studies assessing the concordance of antemortem and postmortem causes of death should include moderator analyses between the timing that antemortem diagnoses were made and postmortem causes of death. Furthermore, we did not assess whether diagnoses made by clinicians were for previously known chronic diseases (eg, chronic HIV disease) or new illnesses (eg, newly diagnosed HIV). Nevertheless, as our reference standard was robust postmortem determined causes of death that includes immediate, underlying and comorbid causes of death we do not expect this to have substantially affected our results. Some of the diagnoses considered discrepant, such as aspiration pneumonia, sepsis and interstitial lung disease, may reflect the natural progression of a primary illness rather than distinct, avertable causes of death, complicating the distinction between initial illness and subsequent conditions. Additionally, the diagnostic capabilities and skills of clinicians across sites vary and likely depend on the level of training of medical staff, which was not measured in this study. We did not separately analyse immediate, underlying and comorbid postmortem causes of death in relation to antemortem diagnoses. The classification system used to categorise major antemortem diagnostic errors does not necessarily indicate there was also an error in clinical management or treatment that could have prevented the child's death. Some major errors may have still received appropriate supportive care, such as fluids, oxygen and antibiotics, which treat many conditions. Thus, while major diagnostic errors suggest potential opportunities to prevent mortality, it is difficult to quantify how many deaths were realistically avoidable. Some of the diagnoses considered discrepant, such as aspiration pneumonia, sepsis and interstitial lung disease, may reflect the natural progression of a primary illness rather than distinct, avertable causes of death, complicating the distinction between initial illness and subsequent conditions. We also did not capture the reasons clinicians made antemortem diagnoses or the use of equipment for diagnoses such as malnutrition through measurement of anthropometry, which warrants further investigation. Such an understanding may elucidate precise diagnostic challenges in need of targeted interventions to overcome. The relatively low specificity of antemortem diagnosis of diarrhoeal diseases could potentially be attributed to diarrhoea as a symptom accompanying other illnesses determined as the postmortem causes of death. Postmortem causes of death in CHAMPS are determined through a multifaceted approach that includes the integration of antemortem clinical

Open access

diagnoses in addition to histopathological and microbiological MITS results. Lastly, our findings, although drawn from seven sites low-income and middle-income countries, may not represent the state of diagnostic accuracy in other settings in those countries or, more broadly, in sub-Saharan Africa and Bangladesh where postmortem examinations do not routinely occur.

CONCLUSIONS

Antemortem clinical diagnostic errors were common among infants and children who died in seven regions in sub-Saharan Africa and Bangladesh with high childhood mortality rates. Comparing antemortem clinical diagnoses to postmortem causes of death may inform disease processes in most need of enhanced antemortem diagnostic approaches. Most antemortem clinical diagnostic errors were major. To further reduce childhood mortality in resource-limited settings, there is an urgent need to improve antemortem diagnostic capability through advances in availability of diagnostic testing and clinical skills.

Author affiliations

¹College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia ²Hararghe Health Research, Haramaya University, Harar, Ethiopia

³London School of Hygiene & Tropical Medicine, London, UK

⁴Children's Hospital of Philadelphia Pediatrics Residency Program, Philadelphia, Pennsylvania, USA

⁵Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya

⁶Liverpool School of Tropical Medicine, Liverpool, UK

⁷Global Health Institute, Emory University, Atlanta, Georgia, USA

⁸Kisumu County Department of Health, Kisumu, Kenya

⁹Crown Agents, Freetown, Sierra Leone

¹⁰Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

¹¹Department of Community Medicine, University of Calabar, Calabar, Cross River, Nigeria

¹²Bernard Lown Scholars Program in Cardiovascular Health, Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

¹³International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh

¹⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

¹⁵Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA

¹⁶Centre pour le Développement des Vaccins-Mali, Bamako, Mali

¹⁷Centro de Investigação em Saúde de Manhiça [CISM], Maputo, Mozambique
 ¹⁸ISGlobal - Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

¹⁹ICREA, Pg. Lluís Companys 23, 08010, Barcelona, Spain

²⁰Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain

²¹CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain

²²Department of Pathology, Maputo Central Hospital, Maputo, Mozambique
²³Department of Pathology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique

²⁴South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa

²⁵Department of Anatomical Pathology, University of the Witwatersrand Johannesburg, Johannesburg, South Africa ²⁶Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

²⁷Infectious Diseases Pathology Branch, NCEZID, DHCPP, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

²⁸Infectious Diseases and Oncology Research Institute, University of the Witwatersrand, Johannesburg, South Africa

²⁹Pediatric Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Acknowledgements We thank the families of the deceased children included in this study, and the CHAMPS Network members across all seven sites for their contributions to make this research possible. We are thankful for the funding of the Bill & Melinda Gates Foundation.

Collaborators Child Health and Mortality Prevention Surveillance (CHAMPS) network: Fatima Solomon, Gillian Sorour, Hennie Lombaard, Jeannette Wadula, Karen Petersen, Nelesh P Govender, Peter J Swart, Sanjay G Lala, Sithembiso Velaphi, Richard Chawana, Yasmin Adam, Amy Wise, Ashleigh Fritz, Nellie Myburgh, Pedzisai Ndagurwa, Cleopas Hwinya, Sanwarul Bari, Shahana Parveen, Mohammed Kamal, ASM Nawshad Uddin Ahmed, Mahbubul Hoque, Saria Tasnim, Ferdousi Islam, Farida Ariuman, Mohammad Mosiur Rahman, Ferdousi Begum K Zaman, Mustafizur Rahman, Dilruba Ahmed, Meerjady Sabrina Flora, Tahmina Shirin, Mahbubur Rahman, Joseph Oundo, Alexander M Ibrahim, Fikremelekot Temesgen, Tadesse Gure, Melisachew Mulatu Yeshi, Mahlet Abayneh Gizaw, Stian MS Orlien, Solomon Ali, Peter Otieno, Peter Nvamthimba Onvango, Janet Agava, Richard Oliech, Joyce Akinyi Were, Dickson Gethi, Sammy Khagayi, George Aol, Thomas Misore, Harun Owuor, Christopher Muga, Bernard Oluoch, Christine Ochola, Sharon M Tennant, Carol L Greene, Ashka Mehta, J Kristie Johnson, Brigitte Gaume, Adama Mamby Keita, Rima Koka, Karen D Fairchild, Diakaridia Kone, Sharon M Tennant, Carol L Greene, Ashka Mehta, Diakaridia Sidibe, Doh Sanogo, Uma U Onwuchekwa, Cheick Bougadari Traore, Jane Juma, Kounandji Diarra, Awa Traore, Tiéman Diarra, Kiranpreet Chawla, Tacilta Nhampossa, Zara Manhigue, Sibone Mocumbi, Clara Menéndez, Khátia Munguambe, Ariel Nhacolo, Maria Maixenchs, Fatmata Bintu Tarawally, Martin Seppeh, Ronald Mash, Julius Ojulong, Babatunde Duduyemi, James Bunn, Alim Swaray-Deen, Joseph Bangura Amara Jambai, Margaret Mannah, Okokon Ita, Cornell Chukwuegbo, Sulaiman Sannoh, Princewill Nwajiobi, Erick Kaluma, Oluseyi Balogun, Carrie Jo Cain, Solomon Samura, Samuel Pratt, Francis Moses, Tom Sesay, James Squire, Joseph Kamanda Sesay, Osman Kaykay, Binyam Halu, Hailemariam Legesse, Francis Smart, Sartie Kenneh, Sartie Kenneh, Jana Ritter, Tais Wilson, Jonas Winchell, Jakob Witherbee, Navit T Salzberg, Jeffrey P Koplan Margaret Basket, Ashutosh Wadhwa, Kyu Han Lee, Roosecelis Martines, Shamta Warang, Maureen Diaz, Jessica Waller, Shailesh Nair, Lucy Liu, Courtney Bursuc, Kristin LaHatte, Sarah Raymer, John Blevins Solveig Argeseanu, Kurt Vyas, Manu Bhandari.

Contributors CGW and RFB secured the funding. HL, CB, CGW and CAR conceptualised and designed the study, interpreted the data and wrote the first draft of the manuscript. ZJM verified the underlying data and conducted the statistical analyses. HL, CB, KAI, VA, DO, RO, IUO, SA, AM, DK, I-AB, SEA, ESG, MZH, AR, MA, NA, LM, AA, KK, SOS, MT, NK, SS, QB, RV, IM, CC, NR, FF, SMadhi, ZD, SMahtab, MH, VB, JdT, ZJM, DB, RBM, PCM, RFB, CGW and CR oversaw data collection, verified the underlying data, assisted with the interpretation of the data and reviewed and provided input to the final draft. HL and CAR had final responsibility for the decision to submit for publication. CAR is responsible for the overall content as the quarantor.

Funding The Child Health and Mortality Prevention Surveillance (CHAMPS) network is funded by the Bill & Melinda Gates Foundation (grant number OPP1126780), which actively contributed to site selection decisions and the methodology and scope of the CHAMPS project. CR was supported by the National Institutes of Health (K23HL173694). In accordance with the grant conditions set forth by the Foundation, a Creative Commons Attribution 4.0 Generic Licence has been designated for the Author Accepted Manuscript version that may result from this submission.

Disclaimer The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the US Centers for Disease Control and Prevention.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and all studies included in this deidentified dataset were previously granted clearance by ethical review boards from each participating site (no number provided for use of deidentified data) and by Emory University Rollins School of Public Health (#IRB0091706). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Data may be made available on reasonable request to the corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

6

Lola Madrid http://orcid.org/0000-0003-4034-6033 Quique Bassat http://orcid.org/0000-0003-0875-7596 Inacio Mandomando http://orcid.org/0000-0002-1078-2187 Zachary J Madewell http://orcid.org/0000-0002-5667-9660 Chris A Rees http://orcid.org/0009-0005-7268-4346

REFERENCES

- 1 GBD 2019 Demographics Collaborators. Global age-sexspecific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;396:1160–203.
- 2 World Health Organization. Child mortality (under 5 years). 2022. Available: https://www.who.int/news-room/fact-sheets/detail/levelsand-trends-in-child-under-5-mortality-in-2020 [Accessed 2 May 2023].
- 3 UNICEF. Africa key facts and figures for child mortality. 2020. Available: https://data.unicef.org/resources/children-in-africa-childsurvival-brochure [Accessed 21 Aug 2023].
- 4 Burstein R, Henry NJ, Collison ML, et al. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature New Biol 2019;574:353–8.
- 5 Madewell ZJ, Whitney CG, Velaphi S, *et al*. Prioritizing health care strategies to reduce childhood mortality. *JAMA Netw Open* 2022;5:e2237689.
- 6 Slusher TM, Kiragu AW, Day LT, et al. Pediatric critical care in resource-limited settings-overview and lessons learned. Front Pediatr 2018;6:49.
- 7 Peeling RW, Mabey D. Point-of-care tests for diagnosing infections in the developing world. *Clin Microbiol Infect* 2010;16:1062–9.
- 8 English M, Aluvaala J, Maina M, et al. Quality of inpatient paediatric and newborn care in district hospitals: WHO indicators, measurement, and improvement. *Lancet Glob Health* 2023;11:e1114–9.
- 9 Rees CA, Igunza KA, Madewell ZJ, et al. Clinical care guideline adherence among infants and children who died in seven countries in the child health and mortality prevention surveillance (CHAMPS) network. E Clin Med 2023;63:102198.
- 10 Menéndez C, Quintó L, Castillo P, et al. Quality of care and maternal mortality in a tertiary-level hospital in Mozambique: a retrospective study of clinicopathological discrepancies. *Lancet Glob Health* 2020;8:e965–72.
- 11 von Dessauer B, Velozo L, Benavente C, et al. Postmortem studies in the contemporary pediatric intensive care unit. *Pediatr Crit Care Med* 2011;12:617–21.

- 12 Pinto Carvalho FL, Cordeiro JA, Cury PM. Clinical and pathological disagreement upon the cause of death in a teaching hospital: analysis of 100 autopsy cases in a prospective study. *Pathol Int* 2008;58:568–71.
- 13 Cifra CL, Jones KL, Ascenzi JA, *et al.* Diagnostic errors in a PICU: insights from the morbidity and mortality conference. *Pediatr Crit Care Med* 2015;16:468–76.
- 14 Breiman RF, Blau DM, Mutevedzi P, *et al.* Postmortem investigations and identification of multiple causes of child deaths: an analysis of findings from the child health and mortality prevention surveillance (CHAMPS) network. *PLOS Med* 2021;18:e1003814.
- 15 Taylor AW, Blau DM, Bassat Q, et al. Initial findings from a novel population-based child mortality surveillance approach: a descriptive study. Lancet Glob Health 2020;8:e909–19.
- 16 Raghunathan PL, Madhi SA, Breiman RF. Illuminating child mortality: discovering why children die. *Clin Infect Dis* 2019;69:S257–9.
- 17 Blau DM, Caneer JP, Philipsborn RP, et al. Overview and development of the child health and mortality prevention surveillance determination of cause of death (DeCoDe) process and DeCoDe diagnosis standards. *Clin Infect Dis* 2019;69:S333–41.
- 18 Salzberg NT, Sivalogan K, Bassat Q, et al. Mortality surveillance methods to identify and characterize deaths in child health and mortality prevention surveillance network sites. *Clin Infect Dis* 2019;69:S262–73.
- 19 Paganelli CR, Goco NJ, McClure EM, *et al.* The evolution of minimally invasive tissue sampling in postmortem examination: a narrative review. *Glob Health Action* 2020;13:1792682.
- 20 Hailu R, Desta T, Bekuretsion Y, *et al.* Minimally invasive tissue sampling in preterm deaths: a validation study. *Glob Pediatr Health* 2020;7:2333794X2095326.
- 21 Bassat Q, Castillo P, Martínez MJ, et al. Validity of a minimally invasive autopsy tool for cause of death determination in pediatric deaths in Mozambique: an observational study. *PLoS Med* 2017;14:e1002317.
- 22 Diaz MH, Waller JL, Theodore MJ, et al. Development and implementation of multiplex TaqMan array cards for specimen testing at child health and mortality prevention surveillance site laboratories. *Clin Infect Dis* 2019;69:S311–21.
- 23 Martines RB, Ritter JM, Gary J, et al. Pathology and telepathology methods in the child health and mortality prevention surveillance network. *Clin Infect Dis* 2019;69:S322–32.
- 24 Bassat Q, Blau DM, Ogbuanu IU, *et al.* Causes of death among infants and children in the child health and mortality prevention surveillance (CHAMPS) network. *JAMA Netw Open* 2023;6:e2322494.
- 25 Battle RM, Pathak D, Humble CG, et al. Factors influencing discrepancies between premortem and postmortem diagnoses. JAMA 1987;258:339–44.
- 26 Goldman L, Sayson R, Robbins S, *et al*. The value of the autopsy in three medical eras. *N Engl J Med* 1983;308:1000–5.
- 27 McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med* 2012;22:276–82.
- 28 Ruopp MD, Perkins NJ, Whitcomb BW, et al. Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. *Biom J* 2008;50:419–30.
- 29 Peng J, Deng X, Wang G, et al. A retrospective analysis of pathological and clinical diagnoses: report of 240 pediatric autopsies. *Fetal Pediatr Pathol* 2012;31:63–73.
- 30 Yadav H, Shah D, Sayed S, et al. Availability of essential diagnostics in ten low-income and middle-income countries: results from national health facility surveys. *Lancet Glob Health* 2021;9:e1553–60.
- 31 Rees CA, Basnet S, Gentile A, et al. An analysis of clinical predictive values for radiographic pneumonia in children. BMJ Glob Health 2020;5:e002708.
- 32 Rees CA, Colbourn T, Hooli S, *et al.* Derivation and validation of a novel risk assessment tool to identify children aged 2-59 months at risk of hospitalised pneumonia-related mortality in 20 countries. *BMJ Glob Health* 2022;7:e008143.
- 33 Darmstadt GL, Baqui AH, Choi Y, et al. Validation of a clinical algorithm to identify neonates with severe illness during routine household visits in rural Bangladesh. Arch Dis Child 2011;96:1140–6.
- 34 World Health Organization. World malaria report 2022. 2022. Available: https://www.who.int/teams/global-malaria-programme/ reports/world-malaria-report-2022 [Accessed 14 Aug 2023].
- 35 Schubert G, Achi V, Ahuka S, et al. The African network for improved diagnostics, epidemiology and management of common infectious agents. BMC Infect Dis 2021;21:539.